Email Facebook Twitter

London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis Watch Now

London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis
Angus Energy in talks to buy 'transformational' gas asset in North England

Glaxosmithkline Share News (GSK)

Stock Market news at - RSS News Feeds

Share News for Glaxosmithkline (GSK)

Share Price: 1,543.40Bid: 1,601.60Ask: 1,461.80Change: -11.60 (-0.75%)Faller - Glaxosmithkline
Spread: -139.80Spread as %: -8.73%Open: 1,544.00High: 0.00Low: 0.00Yesterday’s Close: 1,555.00

Amicus shares fall after Fabry drug fails late-stage study

Thu, 20th Dec 2012 16:02

Dec 20 (Reuters) - Amicus Therapeutics Inc lost nearly half of its market
value after the company said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage study.

The company's shares were down 43 percent at $3.28 in early trading on Thursday on the Nasdaq. The stock had gained about 85 percent up to the close on Wednesday this year.

Amicus said on Wednesday that six-month data from the study showed that the drug, Amigal, did not significantly cut down the amount of a kind of fat in kidney blood vessels in Fabry disease patients, compared to a placebo.

Fabry disease is caused by the body's inability to produce the enzyme that helps breaks down fat.

Amigal, being developed in partnership with British drugmaker GlaxoSmithKline Plc, is Amicus's most advanced pipeline product.

The news prompted at least three analysts to cut their price targets on the stock, and cast doubts on chances of the drug proving strong enough to be approved as a stand-alone therapy.

Capstone Investments analyst Mayank Gandhi said Amigal data may not be sufficient to convince clinicians to use it as a stand-alone therapy, compared to the strong efficacy proven by Fabrazyme, the only enzyme replacement therapy for the disease from Sanofi SA's unit Genzyme.

Canaccord Genuity analyst Ritu Baral cut her price target on the stock to $6 from $11.

Leerink Swann analyst Joseph Schwartz said probability of success for Amigal as a stand-alone therapy was 25 percent now from 75 percent earlier.

Amicus also said the U.S. Food and Drug Administration indicated that it will consider the 12-month efficacy and safety data from the study.

'Should we see extremely strong evidence of stabilization of functional renal endpoints at 12 months, as well as supportive GL-3 data, there may be a chance Amicus will file for and receive approval,' Canaccord Genuity's Baral said.

The companies expect 12-month data from the study in the first half of 2013.

(Reporting by Vidya P L Nathan; Editing by Sriraj Kalluvila) Keywords: AMICUSTHERAPEUTICS SHARES/

( U.S. +1 646 223 8780)(outside U.S. +91 80 4135 5800)(Reuters Messaging:

Copyright Thomson Reuters 2012. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

Trade rhetoric weighs on European shares

(For a live blog on European stocks, type LIVE/ in an Eikon news window)May 17 (Reuters) - European shares dropped on Friday after three days of gains
[17 May '19 08:03]

Ex-divs to take 23.6 points off FTSE 100 on May 16

MILAN, May 13 (Reuters) - The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the lates
[13 May '19 09:55]

UK regulator investigates China's state broadcaster for airing TV confession

LONDON, May 8 (Reuters) - Britain's broadcasting watchdog has launched a formal investigation into whether a confession made by a British man and aire
[8 May '19 15:14]

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.

May 4 (Reuters) - British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc i
[4 May '19 17:24]

UPDATE 1-GSK's 3-in-1 inhalable drug shows promise in asthma study

(Adds background on market opportunity)May 2 (Reuters) - British drugmaker GlaxoSmithKline Plc said on Thursday that its three-in-one drug Trelegy met
[2 May '19 18:41]

UPDATE 4-GSK sees shingles vaccine sales rising, as free cash flow concerns weigh

(Adds details on respiratory drugs performance)* Vaccines unit sales surge 20 percent, led by Shingrix* Shingrix sales to be "significantly" more than
[1 May '19 12:29]

UPDATE 2-Oil firms, exporters drag FTSE 100, while Sainsbury's, LSE outshine

* FTSE 100 down 0.4 pct* FTSE 250 down 0.1 pct* Oil majors, international firms weigh* Sainsbury's jumps on profit beat* Lloyds gains on hopes of more
[1 May '19 09:39]

UPDATE 2-Oil heavyweights, exporters guide FTSE 100 close to 7-month high

* FTSE 100 up 0.9 pct* FTSE 250 up 0.3 pct* Oil majors take main index higher* Oil price surge hits airlines* Softer sterling boosts exporter stocks*
[23 Apr '19 09:48]

Share Price, Share Chat, Stock Market news at
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.